Andrea Bianchi1, Sandrine Dufort2, 3, Franois Lux4, Jean-Luc Coll2, Olivier Tillement4, Yannick Crmillieux1
1Cardio-Thoracic Center of Bordeaux, University of Bordeaux Segalen, Bordeaux, France, France; 2University Joseph Fourier, Saint-Martin-d'Hres, France, France; 3Nano-H, Saint Quentin - Fallavier, France, France; 4Laboratoire de Physico-Chimie des Matriaux Luminescents, University Claude Bernard, Villeurbanne, France, France
Intratracheal administration of contrast agents based on nanostructures is a promising approach in the diagnosis of lung diseases. The characterization of contrast media pharmacokinetics (PK) and elimination pathways is fundamental to understand the potential of a given contrast agent and its toxicity, main limiting factor in the translatability of preclinical to clinical studies. We present here an in vivo MRI study of the PK and biodistribution of Gd-based intratracheally-administrated multimodal Ultra-Small Rigid Platforms (USRPs) and of a commercially available Gd-based contrast agent. The implemented MRI PK models for lungs and kidneys were validated against optical imaging.